Alzamend Neuro, Inc. (ALZN) stock
ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30
$1.04−0.09 (-7.96%)
Close on Nov 18, 2026Market cap $5.02MP/E –Yield –
Alzamend Neuro total assets
Total assets on the balance sheet at the end of each period.
Alzamend Neuro's total assets was $8.54M at Jul 31, 2026. For fiscal 2026 it was $2.08M, down 54.8% from the year before. The highest annual figure on record is $14.52M in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | $2.08M | -54.8% |
| FY2025 | Apr 30, 2025 | $4.60M | +628.8% |
| FY2024 | Apr 30, 2024 | $631.59K | -89.3% |
| FY2023 | Apr 30, 2023 | $5.92M | -59.2% |
| FY2022 | Apr 30, 2022 | $14.52M | +398.4% |
| FY2021 | Apr 30, 2021 | $2.91M | +60.6% |
| FY2020 | Apr 30, 2020 | $1.81M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | $8.54M | +35.0% |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | $2.08M | -54.8% |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | $4.04M | +142.0% |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | $5.09M | +706.2% |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | $6.33M | +708.4% |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | $4.60M | +368.0% |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | $1.67M | -36.5% |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | $631.59K | -89.3% |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | $782.64K | -90.8% |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | $983.60K | -90.6% |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | $2.63M | -78.5% |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | $5.92M | -59.2% |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | $8.50M | -31.6% |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | $10.42M | -28.1% |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | $12.21M | -27.4% |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | $14.52M | +398.4% |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | $12.43M | +585.2% |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | $14.50M | – |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | $16.82M | – |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | $2.91M | – |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | $1.81M | – |
See a number that looks wrong?